

ISTA Pharmaceuticals

[View the current ISTA Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24934-ISTA+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/24934-ISTA+Pharmaceuticals.html>)

Contact Details:

15295 Alton Parkway

Irvine

California

92618

United States of America

Tel: (949) 788-6000

Fax: (949) 788-6010

Email:

ISTA Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products for serious conditions of the eye. ISTA has three approved products, Xibrom™ (for the treatment of ocular inflammation following cataract surgery), Istalol® (for the treatment of glaucoma) and Vitrase® (for use as a "spreading agent"). We launched Istalol® during Q3 2004, Vitrase® during Q1 2005 and Xibrom™ during Q2 2005. We have received an approvable letter for Vitrase® (for the treatment of vitreous hemorrhage). We have other prescription products under development, including a tobramycin prednisolone acetate for the treatment of inflammation where a bacterial infection might be present, ecabet sodium, for the treatment of dry eye, and Caprogel® for the treatment of hyphema. In order to further build our pipeline as a specialty pharmaceutical company, we expect to acquire complementary products in ophthalmology, either already marketed or in late-stage development. ISTA has been well financed, and our management team has extensive experience in the development and commercialization of ophthalmic pharmaceuticals.

Recent Publications by ISTA Pharmaceuticals:



- [24-hour evaluation of the ocular distribution of \(14\)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.](#)

PURPOSE: The aim of this study was to determine the distribution and...6th January, 2009

ISTA Pharmaceuticals(R), Inc., Irvine, CA 92618, USA.- J Ocul Pharmacol Ther. 2008

Aug;24(4):392-8. ([DOI Direct Link](#))

- [Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes.](#)

PURPOSE: The aim of this study was to evaluate the pharmacokinetic...17th December, 2008

ISTA Pharmaceuticals,- J Ocul Pharmacol Ther. 2008 Oct;24(5):507-12. ([DOI Direct Link](#))

- [Pupil dilatation in response to vagal afferent electrical stimulation is mediated by inhibition of parasympathetic outflow in the rat.](#)
*Pupil dilatation (PD) was produced by vaginocervical mechanical...*16th January, 2008
Clinical Research, ISTA Pharmaceuticals, Inc. 15295 Alton Parkway, Irvine,- Brain Res. 2007 Oct 26;1177:29-36. Epub 2007 Aug 11. ([DOI Direct Link](#))
- [Licensing Compounds: lessons from ISTA Pharmaceuticals.](#)
*Pupil dilatation (PD) was produced by vaginocervical mechanical...*2nd March, 2006
ISTA Pharmaceuticals, Irvine, CA, USA.- Retina. 2005 Dec;25(8 Suppl):S98.
- [Crucial factors in commercial success for ophthalmic drugs.](#)
*Pupil dilatation (PD) was produced by vaginocervical mechanical...*2nd March, 2006
ISTA Pharmaceuticals, Inc., Irvine, CA, USA.- Retina. 2005 Dec;25(8 Suppl):S109.
- [Fomivirsen.](#)
*Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients...*28th May, 2003
ISTA Pharmaceuticals (previously Isis Pharmaceuticals, Inc.), Irvine,- Drugs Today (Barc). 2001 Apr;37(4):245-255.

Press Releases on ISTA Pharmaceuticals:

Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	

[Reportlinker Adds](#)

[Intranasal Drug Delivery - US Market Trends & Analysis](#) 25th November, 2009 Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: *Intranasal Drug Delivery - US Market Trends & Analysis* <http://www>

BioNews Results for ISTA Pharmaceuticals



- [Research and Markets: Ophthalmic Pharmaceutical Drugs - A Global Market Perspective](#)
SmartBrief: Nov 19 2009 4:16PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Entrepreneur.com: Nov 11 2009 11:11AM Matching: ista pharmaceuticals
- [Medical News: ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma & Immunology \(ACAAI\)](#)
BioFind: Nov 10 2009 12:40PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data At The 2009 Annual Meeting Of The American College O](#)
Medical News Today: Nov 10 2009 9:27AM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve Clinical Data at the 2009 Annual Meeting of the American College of AI](#)
Pharma Live: Nov 10 2009 9:38PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Pharmacy Choice: Nov 9 2009 8:41PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
PR Newswire: Nov 9 2009 2:28PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Therapeutics Daily: Nov 9 2009 1:51PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Boston Business Journal: Nov 9 2009 1:46PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Orlando Business Journal: Nov 9 2009 1:37PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Sacramento Business Journal: Nov 9 2009 1:14PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)
Yahoo! Canada: Nov 9 2009 12:53PM Matching: ista pharmaceuticals
- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the](#)

[American College o](#)

Houston Chronicle: Nov 9 2009 12:51PM Matching: ista pharmaceuticals

- [ISTA Pharmaceuticals Highlights Bepreve\(TM\) Clinical Data at the 2009 Annual Meeting of the American College o](#)

PR Newswire via Yahoo!: Nov 9 2009 12:47PM Matching: ista pharmaceuticals

- [ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies](#)

News-Medical.Net: Nov 9 2009 7:41PM Matching: ista pharmaceuticals

ISTA Pharmaceuticals Patents:



- 7141610- [Compositions and methods for the induction of retinal detachments](#)
- 7115408- [Method of stabilizing hyaluronidase with annexin II](#)
- 6939542- [Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye](#)
- 6737075- [Biochemical methods that eliminate corneal scars, opacification and haze](#)
- 6610292- [Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders](#)
- 6551590- [Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vireous body of the eye](#)
- 6537545- [Use of corneal hardening agents in enzymeorthokeratology](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCororporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

